Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | MGAM | O43451 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | SI | P14410 | 4/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | APAF1 | O14727 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148211 | 0.88 | MAPT (0.68) | KMT2AMAPTMEN1PKMGPR84 | |
| SCHEMBL20553142 | 0.83 | GPR84 (0.68) | KMT2AMAPTMEN1PKMGPR84 | |
| SCHEMBL4860329 | 0.83 | GPR84 (0.68) | KMT2AMAPTMEN1PKMGPR84 | |
| SCHEMBL15747689 | 0.83 | GPR84 (0.59) | KMT2AMAPTMEN1PKMGPR84 | |
| SCHEMBL15747714 | 0.81 | MAPT (0.59) | KMT2AMAPTMEN1PKMGPR84 | |
| SCHEMBL4858383 | 0.81 | MEN1 (0.61) | KMT2AMAPTMEN1PKMGPR84 | |
| SCHEMBL21067833 | 0.81 | MEN1 (0.61) | KMT2AMAPTMEN1PKMGPR84 | |
| SCHEMBL6835648 | 0.80 | MAPT (0.76) | KMT2AMAPTMEN1PKMGPR84 | |
| SCHEMBL2932417 | 0.80 | MAPT (0.76) | KMT2AMAPTMEN1PKMGPR84 | |
| SCHEMBL11269915 | 0.80 | MEN1 (0.68) | KMT2AMAPTMEN1PKMGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11147796-B2 | Agent for preventing or ameliorating hearing impairment | TOHOKU UNIVERSITY (JP) | 2021-10-19 | — | — | US | disclosed |
| US-11147796-B2 | Agent for preventing or ameliorating hearing impairment | TOHOKU UNIVERSITY (JP) | 2021-10-19 | — | — | US | disclosed |
| US-10869858-B2 | Therapeutic agent for amyotrophic disorders | TOHOKU UNIVERSITY (JP) | 2020-12-22 | — | — | US | disclosed |
| US-10869858-B2 | Therapeutic agent for amyotrophic disorders | TOHOKU UNIVERSITY (JP) | 2020-12-22 | — | — | US | disclosed |
| US-10463647-B2 | Erythropoietin expression promoter | TOHOKU UNIVERSITY (JP) | 2019-11-05 | — | — | US | disclosed |
| US-10463647-B2 | Erythropoietin expression promoter | TOHOKU UNIVERSITY (JP) | 2019-11-05 | — | — | US | disclosed |
| US-20190224165-A1 | Agent for Preventing or Ameliorating Hearing Impairment | TOHOKU UNIVERSITY (JP) | 2019-07-25 | — | — | US | disclosed |
| US-20190224165-A1 | Agent for Preventing or Ameliorating Hearing Impairment | TOHOKU UNIVERSITY (JP) | 2019-07-25 | — | — | US | disclosed |
| US-20190054066-A1 | THERAPEUTIC AGENT FOR AMYOTROPHIC DISORDERS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-02-21 | — | — | US | disclosed |
| US-20190054066-A1 | THERAPEUTIC AGENT FOR AMYOTROPHIC DISORDERS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-02-21 | — | — | US | disclosed |
| US-10004718-B2 | Erythropoietin expression promoter | TOHOKU UNIVERSITY (JP) | 2018-06-26 | — | — | US | disclosed |
| US-10004718-B2 | Erythropoietin expression promoter | TOHOKU UNIVERSITY (JP) | 2018-06-26 | — | — | US | disclosed |
| CN-104936591-B | Hematopoietin expression facilitator | 国立大学法人东北大学 | 2018-05-29 | — | — | CN | disclosed |
| US-20150353489-A1 | Erythropoietin Expression Promoter | KANAGAWA PREFECTURAL HOSPITAL ORGANIZATION KANAGAWA CHILDREN'S MEDICAL CENTER (JP) | 2015-12-10 | — | — | US | disclosed |
| US-20150353489-A1 | Erythropoietin Expression Promoter | KANAGAWA PREFECTURAL HOSPITAL ORGANIZATION KANAGAWA CHILDREN'S MEDICAL CENTER (JP) | 2015-12-10 | — | — | US | disclosed |
| US-20150353489-A1 | Erythropoietin Expression Promoter | KANAGAWA PREFECTURAL HOSPITAL ORGANIZATION KANAGAWA CHILDREN'S MEDICAL CENTER (JP) | 2015-12-10 | — | — | US | disclosed |
| EP-2923700-A1 | ERYTHROPOIETIN EXPRESSION PROMOTER | Tohoku University (JP) | 2015-09-30 | — | — | EP | disclosed |
| EP-2923700-A1 | ERYTHROPOIETIN EXPRESSION PROMOTER | Tohoku University (JP) | 2015-09-30 | — | — | EP | disclosed |
| CN-104936591-A | Erythropoietin expression promoter | UNIV TOHOKU NAT UNIV CORP | 2015-09-23 | — | — | CN | disclosed |
| WO-2014080640-A1 | ERYTHROPOIETIN EXPRESSION PROMOTER | 国立大学法人東北大学 (JP) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11147796-B2 | Agent for preventing or ameliorating hearing impairment | SLC26A4, OTC, SLC25A20 | KMT2A 4378/4885MAPT 4510/4885MEN1 1339/4885 |
| US-20150353489-A1 | Erythropoietin Expression Promoter | EPOR, NFE2L2, FOXO1 | KMT2A 3254/4885MAPT 4882/4885MEN1 3086/4885 |
| US-20190054066-A1 | THERAPEUTIC AGENT FOR AMYOTROPHIC DISORDERS | SMN1; SMN2, MYOF, MUSK | KMT2A 3952/4885MAPT 747/4885MEN1 4421/4885 |
| US-20190224165-A1 | Agent for Preventing or Ameliorating Hearing Impairment | SLC26A4, OTC, SLC25A20 | KMT2A 4378/4885MAPT 4510/4885MEN1 1339/4885 |
| US-10869858-B2 | Therapeutic agent for amyotrophic disorders | SMN1; SMN2, MYOF, MUSK | KMT2A 3952/4885MAPT 747/4885MEN1 4421/4885 |
| US-10004718-B2 | Erythropoietin expression promoter | EPOR, NFE2L2, FOXO1 | KMT2A 3254/4885MAPT 4882/4885MEN1 3086/4885 |
| US-10463647-B2 | Erythropoietin expression promoter | EPOR, NFE2L2, FOXO1 | KMT2A 3254/4885MAPT 4882/4885MEN1 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.